<DOC>
	<DOCNO>NCT01646073</DOCNO>
	<brief_summary>A study evaluate safety efficacy adalimumab Chinese subject moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Safety Efficacy Study Adalimumab Treatment Plaque Psoriasis</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy adalimumab determine well work treatment adult moderate severe plaque psoriasis Chinese population . Psoriasis chronic immunologic disease characterize marked inflammation thicken epidermis result thick , scaly plaque involve skin .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Clinical diagnosis psoriasis least 6 month . Must stable plaque psoriasis least 2 month screen baseline visit . Participant must Psoriasis Area Severity Index score great equal 10 baseline visit . Participant must moderate severe plaque Psoriasis , define Body Surface Area involvement great equal 10 % baseline visit . Participant must Physicians Global Assessment least moderate disease baseline visit . Diagnosis active skin disease skin infection . Participant known hypersensitivity adalimumab excipients . Participant chronic recur infection active tuberculosis . Participant demyelinate disease ( include myelitis ) neurologic symptom suggestive demyelinate disease . Participant know immune deficiency immunocompromised .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Placebo Controlled</keyword>
	<keyword>Skin Disease</keyword>
	<keyword>Double Blind</keyword>
</DOC>